Call for Abstracts

1Submission Period

Date: October 22 (Fri.) – 
December 15 (Wed.), 2021 (UTC+9)
Abstract Submission is extended to December 22 (Wed.), 2021 (UTC+9)
We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.

2Category

Symposium (applicable)

Pathophysiological research
Clinical research
Immune Therapy

Workshop

Pathophysiological research
Clinical research１ (Diagnostic procedure, Biomarker)
Clinical research２ (Treatment)
Clinical research３ (Others)
*At the time of abstract submission, please select one of the free paper categories and select whether you wish to be invited to the symposium. If your abstract is not accepted for the symposium, you may request to have your abstract accepted as a free paper presentation.

Basic Program

(1) Basic Research
(2) Pathophysiology and Translational Research
(3) Diagnostic Procedure (including bio-marker) and Disease Entity
(4) NDMM Treatment-Transplant eligible
(5) NDMM Treatment-Transplant-ineligible
(6) RRMM Treatment
(7) Complications, Supportive Care and Comprehensive Care
(8) Myeloma-related Disorders
(9) Case Report
(10) Others

Additional JSM Annual Meeting Presentation Categories (Outside of General Presentation)

For The Annual Meeting of the Japanese Society of Myeloma (JSM Annual Meeting), we have established the following three abstract presentation categories, which are utilized in a wide range of other clinical medicine association conferences, in addition to the general presentation.

(A) Late-Breaking Abstracts (LBA)
Submission Period: December 8 (Wed), 2021 - February 10 (Thu), 2022 (Planned)
*Please refer to  of Late-Breaking Abstracts.
*If you submit both free papers and Late Breaking Abstracts, they will be reviewed as free papers.
1. Late-Breaking Abstracts
(1) We understand that it may not be possible for participants to meet JSM Annual Meeting general presentation abstract submission deadline when presentation content relates to particularly high-value clinical trials. Therefore, we have added the Late-Breaking Abstracts category.
(2) Submissions for this category will be accepted until the absolute final deadline for JSM Annual Meeting submissions. They will not be included in the printed collection of abstracts, but will be included in the digital program collection.
(3) There is a maximum limit to the number of submissions accepted in this category.
(4) Submission requirements are as follows:
  1. The reason(s) for not submitting by the general presentation abstract submission deadline must be deemed acceptable by reviewers, and the submission must exhibit high potential in regard to its scientific value.
  2. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  3. No objection submitted in response to submission review results will be recognized, regardless of selection results and any other factor.
  4. Submissions must be made in accordance with all rules for general presentation submissions.
(B) Trials in Progress (TiP)
Submission Period: 
October 25 (Mon.) – 
December 15 (Wed.), 2021 (UTC+9)
December 22 (Wed.), 2021 (UTC+9)
*Please submit your abstract from the "Abstract submission" button below.
*Please refer to of Trial in Progress.
2. Trials in Progress (TiP)
(1) The TiP category is established for the sake of planned and currently-underway clinical research and other such activities (with a primary focus on clinical research) that have not yet produced analytical or other results and which, through their presentation and discussion at the JSM Annual Meeting, exhibit potential for higher-value influence and impacts based on methodologies and research progress moving forward.
(2) The submission deadline is the same as for general presentation submissions.
(3) There is a maximum limit to the number of submissions accepted in this category.
(4) The following submission requirements must be fulfilled:
  1. The research in question for submission in this category must be fully planned and/or currently underway, with primary endpoint analysis not yet completed at the time of submission.
  2. Discussions on TiP category submissions must enable early involvement by translational researchers, biostatisticians, regulatory specialists and other such researchers in research efforts at clinical facilities, in corporate-led clinical case studies, and similar. Furthermore, TiP-category submissions must have the potential to promote greater numbers of case studies through increased visibility for ongoing clinical research.
  3. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  4. No objection submitted in response to submission review results will be recognized, regardless of selection results and any other factor.
  5. Submissions must be made in accordance with all rules for general presentation submissions.
(C) Encore
Submission Period: 
October 25 (Mon.) – 
December 15 (Wed.), 2021 (UTC+9)
December 22 (Wed.), 2021 (UTC+9)
*Please submit your abstract from the "Abstract submission" button below.
*Please refer to of Encore.
3. Encore Presentation
(1) An abstract which, at the time of submission, is identical to or nearly unchanged from (an adaptation of) an abstract presented previously made at a major overseas conference(s) or similar event within the last year, but which has not been presented yet at a JSM Annual Meeting or other conference or similar event in Japan, may be submitted in this category.
(2) There is a maximum limit to the number of submissions accepted in this category.
(3) The following submission requirements must be fulfilled:
  1. The submitted abstract must have potential to gain new, highly meaningful scientific value through submission to and fresh discussion at the JSM Annual Meeting.
  2. The phrase “(Encore)” must be added to the end of the submission’s title.
  3. If any copyright or similar exists for any part of the submission, the submitter is responsible for obtaining consent for submission and usage.
  4. In the case of copyrighted material usage, if said copyright holder is a scientific association, publishing company or similar, the final portion of the abstract must include a statement indicating that permission for copyrighted content submission and usage has been obtained as well as information on the original copyrighted material (original abstract or similar).
  5. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
  6. No objection submitted in response to submission review results will be recognized, regardless of selection results and any other factor.
  7. Submissions must be made in accordance with all rules for general presentation submissions.

3Guidelines for Abstract Submission

For participants from overseas

All participants from overseas can participate the 47th annual meeting of the JSM ONLY VIRTUALLY, NOT IN-PERSON because of our governmental regulation for the COVID-19 pandemic.

Participants from overseas can submit without membership status, but are required to pay the registration fee. This registration fee is NOT REFUNDABLE despite the result of acceptance/rejection of the submission. This non-refundable condition is the same for the submission by the Japanese members

Registration is scheduled to open in February 2022.

Submission Requirements

The first author (presenter) must be a member of the Japanese Society of Myeloma. Exceptions are permitted for early-career residents in the new training system, non-M.D. graduate students, undergraduate students, international students, and non-Japanese nationals, who may present their abstracts as the first author regardless of membership.

Presentation Format

When submitting your application, please select whether you would like to present a workshop (oral presentation) or a poster presentation.

*Please note that the presentation format is subject to change in order to prevent the spread of COVID-19.
Presentation Awards

Approximately five excellent poster presentations are scheduled to be selected.

JSM Travel Award for IMS/IMW

JSM Travel Award for IMS/IMW is applicable for only the Japanese JSM members.
Conditions of this award appears in the Japanese page. Application forms (Aplication Form, Recommendation Letter, English Abstract, Research Achievements) also appears in the Japanese page.

Abstract Submission and Book of Abstracts

The abstract book will be published by the International Journal of Myeloma to preserve the contents in a format readily available for future citations.
To allow for citations from overseas researchers, please register abstract titles and the body of your abstract in English.

4Character Limit

Title: less than 150 letters
Abstract body: less than 1600 letters = it is about 240 words

 

Free paper submissions must be approved by the Clinical Research Review Board of the required institution at the time of submission and must clearly state any conflicts of interest.

5Submission

All abstracts must be submitted via the conference website.

6Online Registration & Submission

Submission Period
Date: October 22 (Fri.) – 
December 15 (Wed.), 2021 (UTC+9)
Abstract Submission is extended to December 22 (Wed.), 2021 (UTC+9)
We deeply appreciate for Submitting Abstracts.
Abstract Submission has closed.
Instructions:
  • Before proceeding, please read through the following instructions carefully.
  • Information entered on the registration page will be uploaded directly to the database via the Internet.
  • The abstract title, presenter’s name, and affiliation will be used for the preparation of the abstract book.
  • Any changes to the abstract title, presenter’s name, or affiliation after the submission deadline will not be accepted.
  • One application per abstract is required. Please ensure that you enter your email address correctly.
1. Click on “Abstract Submission” below to access the login screen for the 47th Annual Meeting of the Japanese Society of Myeloma. Proceed to click on “Create My LaCool Account” and enter the first author’s personal information. (An automated message will be sent to the email address provided containing a link to set up your password. Therefore, we ask that you please enter your email address correctly.)
Fields marked with an asterisk (*) are required.
2. Click “Next” to open the confirmation page. Please review the details you have entered and if the information is correct, click “Submit”.
3. An automated message will be sent to the registered email address. Please access the link provided in the body of the message, create your password, and click “Next”. *Please keep a record of your ID and password in a safe place.
4. Click “Return to Top (My LaCool)” and the first author’s page (My LaCool) will open. Click on the “New Submission of Papers” button.
5. This will open the “Affiliation Information” entry screen. Please enter the affiliations of all the presenters, including the first author. Please note that the names of the institutions you enter here will be published in the abstract book. Click “Next” to go to the “Top Author Affiliation Information/ Co-authors Information” screen.
6. Please select the name of the first author’s affiliated institution, enter the first names and last names of the co-presenters, click on their affiliated institution name, and click “Next”. Enter information on the co-presenters one by one and click “Submit”. After entering information on all the co-presenters, click “Next”.
7. Next, the “Abstract Information” screen will open. Please select the theme of your abstract, enter both the English and Japanese titles of your abstract, and the English text of your abstract. Click “Next” to confirm your registration details, and then click “Submit”.
8. Once you have successfully completed the registration process, an automated message will be sent to your registered email address to confirm receipt of your abstract and provide you a unique 5-digit Submission ID.
9. During the submission period, you may access your “My LaCool” account at any time to modify or confirm the details of your submission by clicking on your Submission ID. Should you wish to cancel your registered submission, please access “My LaCool” and click on the trash bin icon next to the relevant Submission ID.
*In the event that you do not receive an automated message or are unsure of whether your submission has been processed, please contact the Secretariat at the email address shown below.
*Please note that all future correspondence will be addressed to the first author.
*Please note that the use of figures (diagrams) is not accepted.
*In the last few days prior to the deadline, the site may face increased traffic, and the registration and submission process may be disrupted. It is recommended that submissions be registered as early as possible.
Abstract Submission
Late Breaking Abstracts
December 8 (Web), 2021- February 10 (Thu), 2022

7Regarding the acceptance/rejection of an abstract

The acceptance or rejection of an abstract is at the discretion of the chairperson with program committee. Reasons for rejection will not be disclosed. Notification of acceptance or rejection is scheduled for early March.

8Contact for Abstract Submission Support

c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
TEL: 81-3-3508-1214  FAX: 81-3-3508-1302
E-mail: 47jsm@convention.co.jp

Copyright © The 47th annual Meeting of the Japanese Society of Myeloma All Rights Reserved.